Therapeutic approaches for haemophilia

Bibliography

• LEE C: Recombinant clotting factors in the treatment ofhemophilia. Thromb. Haemost. (1999) 82:516–524.
   PubMed Web of Science ®Google Scholar
• LJUNG RCR: Prophylactic infusion regimens in themanagement of hemophilia. Thromb. Haemost. (1999) 82:525–530.
   PubMed Web of Science ®Google Scholar
• DAVIE EW: Biochemical and molecular aspect of thecoagulation cascade. Thromb. Haemost. (1995) 74:1–6.
   PubMed Web of Science ®Google Scholar
• BERNTORP E: Second generation, B-domain deletedsecondmark Factor VIII. Thromb. Haemost. (1997) 78:256–260.
   PubMed Web of Science ®Google Scholar
• WISE RJ, DORNER AJ et al.: The role of von Willebrandfactor multimers and propeptide cleavage in binding and stabilization of Factor VIII. J. Biol. Chem. (1991) 266:21948–21955.
   PubMed Web of Science ®Google Scholar
• KAUFMAN RJ, PIPE SW: Regulation of Factor VIII expres-sion and activity by von Willebrand factor. Thromb. Haemost. (1999) 82:201–208.
   PubMed Web of Science ®Google Scholar
• •Highlights steps that must be taken into account to improve FVIII secretion and to stabilise the activity of FVIII.
   Google Scholar
• KOEDMAN JA, HAMER RJ, BEESER-VISSER NH et al.: Theeffect of von Willebrand factor on activation of Factor VIII by Factor Xa. Eur. J. Biochem. (1990) 189:229–234.
   PubMedGoogle Scholar
• KOEDMAN JA, MEIJERS JC, SIXMA JJ, BONNA BN: Inacti-vation of Factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J. Clin. Invest. (1988) 82:123–1243.
   Google Scholar
• EATON D, RODRIGUEZ H, VEHAR GA: Proteolyticprocessing of human Factor VIII correlation of specific cleavages by thrombin, Factor Xa and activated protein C with activation and inactivation of Factor VIII coagulant activity. Biochemistry (1986) 25:505–512.
   PubMed Web of Science ®Google Scholar
• FAY PJ, SMUDZIN RM, WALBER FJ: Activated proteinC-catalyzed inactivation of human Factor VIII and Factor VIIIa. Identification of cleavage sites and correlation of proteotype with cofactor activity. J. Biol. Chem. (1991) 266:20139–20145.
   Google Scholar
• PIPE SW, KAUFMAN RJ: Characterization of a genetically inactivation resistant coagulation Factor VIII. Proc. Natl. Acad. Sci. USA (1997) 94:11851–11856.
   PubMed Web of Science ®Google Scholar
• ••Describes potential steps to improve survival of FVIII.
   Google Scholar
• EHRENFORTH S, KREUZ W, SCHARRER I et al.: Incidence of development of Factor VIII and Factor IX inhibitors in hemophiliacs. Lancet (1992) 339:554–598.
   Web of Science ®Google Scholar
• LOZIER JN, BRINKHOUS KM: Gene therapy and the hemophilias. JAMA (1994) 270 (1):47–51.
   Google Scholar
• CONNELLY S, GARDNER JM, LYONS RM, MCCLELLAND A, KALEKO M: Sustained expression of therapeutic levels of human Factor VIII in mice. Blood (1996) 87(104671–4677.
   Web of Science ®Google Scholar
• KAY MA, ROTHENBERG S, LANDEN CN etal.: In vivogene therapy for hemophilia B: sustained partial correction in Factor IX deficient dogs. Science (1993) 262:117–119.
   Google Scholar
• CHUAH MK, COLLEN D, VAN DEN DRIESSCHE T: Genetherapy for hemophilia: hopes and hurdles. Grit. Rev. Oncol. Hematol (1998) 28(3):153–171.
   PubMedGoogle Scholar
• KAUFMAN RJ: Advances toward gene therapy for hemophilia at the millennium. Hum. Gene Ther. (1999) 10(13)2091–2107.
   Google Scholar
• KOEBERL DD, HALBERT CL, KRUMM A, MILLER AD: Sequences within the coding regions of clotting Factor VIII and CFTR block transcriptional elongation. Hum. Gene Ther. (1995) 6:469–479.
   PubMed Web of Science ®Google Scholar
• HOEBEN RC, FALLAUX FJ, CRAMER SJ et al: Expression ofthe blood-clotting Factor VIII cDNA is repressed by a transcriptional silencer located in its coding region. Blood (1995) 85(9):2447–2454.
   PubMed Web of Science ®Google Scholar
• VAN DEN DRIESSCHE T, VAN SLEMBROUCK V, GOOVAERTS I et al.: Long-term expression of human coagulation Factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in Factor VIII-deficient mice. Proc. NatL Acad. Sci. USA (1999) 96(18)10379–10384.
   Google Scholar
• KAY MA, LANDEN CN, ROTHENBERG SR et al.: In vivo hepatic gene therapy: complete albeit transient correction of Factor IX deficiency in hemophilia B dogs. Proc. Natl. Acad. Sci. USA (1994) 91 (6):2353–2357.
   PubMed Web of Science ®Google Scholar
• PARKS RJ, CHEN L, ANTON M, SANKAR U, RUDNICKI MA, GRAHAM FL: A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. USA (1996) 93(24):13565–13570.
   PubMed Web of Science ®Google Scholar
• SANDIG V, YOUIL R, BETT A et al.: Optimization of the helper-dependent adenovirus system for production and potency in vivo. Proc. Natl. Acad. Sci. USA (2000) 97(3):1002–1007.
   PubMed Web of Science ®Google Scholar
• BALAGUR C, ZHOU J, DAI Y et al.: Sustained high-level expression of full-length human Factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector. Blood (2000) 95(3)820–828.
   Google Scholar
• SNYDER RO, MIAO CH, PATIJN GA et al: Persistent and therapeutic concentrations of human Factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nature Genet. (1997) 16(3):270–276.
   PubMed Web of Science ®Google Scholar
• HERZOG RW, HAGSTROM JN, KUNG SH etal: Stable gene transfer and expression of human blood coagulation Factor IX after intramuscular injection of recombinant adeno-associated virus. Proc. Natl. Acad. Sci. USA (1997) 94(11)5804–5809.
   Google Scholar
• SNYDER RO, MIAO C, MEUSE L et al.: Correction of B in canine and murine models using recombinant adeno-associated viral vectors. Nature Med. (1999) 5:64–70.
   PubMed Web of Science ®Google Scholar
• •Highlights the feasibility of using AAV viral vectors for sustained delivery of FIX in vivo.
   Google Scholar
• HERZOG RW, YANG EY, COUTO LB et al.: Long-term of canine hemophilia B by gene transfer of blood coagulation Factor IX mediated by adeno-associated viral vector. Nature Merl. (1999) 5:56–63.
   PubMed Web of Science ®Google Scholar
• •Highlights the feasibility of using AAV viral vectors for sustained delivery of FIX in vivo.
   Google Scholar
• KAY MA, MANNO CS, RAGNI MV et al: Evidence for gene and expression of Factor IX in haemophilia B patients treated with an AAV vector. Nature Genet. (2000) 24(3):257–261.
   PubMed Web of Science ®Google Scholar
• •Highlights the feasibility of using AAV viral vectors for sustained delivery of FIX in vivo.
   Google Scholar
• BURTON M, NAKAI H, COLOSI P et al.: Coexpression of VIII heavy and light chain adeno-associated viral vectors produces biologically active protein. Proc. Natl. Acad. Sci. USA (1999) 96(22):12725–12730.
   PubMed Web of Science ®Google Scholar
• ••Use of separate vectors to deliver FVIII heavy and lightchains to overcome size limitation of AAV for packaging the cDNA of FVIII.
   Google Scholar
• CHAO H, MAO L, BRUCE AT, WALSH CE: Sustained expression of human Factor VIII in mice using a parvovirus-based vector. Blood (2000) 95 (5) :1594–1599.
   PubMed Web of Science ®Google Scholar
• KREN BT, BANDYOPADHYAY P, STEER CJ: In vivo site-directed mutagenesis of the Factor IX gene by chimeric RNA/DNA oligonucleotides. Nature Merl. (1998) 4(3)285–290.
   Google Scholar
• MARSHALL E: Gene therapy death prompts review of adenovirus vector. Science (1999) 286(5448):2244–2245.
   PubMed Web of Science ®Google Scholar
• KONDRO W: Tainted-blood commission. Lancet (1993) 342(8862)40–41.
   Google Scholar